- Home
- BLFS vs COGT Comparison
BLFS vs COGT Comparison
Compare BLFS & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLFS
- COGT
- Stock Information
- Founded
- BLFS 1987
- COGT 2014
- Country
- BLFS United States
- COGT United States
- Employees
- BLFS N/A
- COGT N/A
- Industry
- BLFS Medical/Dental Instruments
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- BLFS Health Care
- COGT Health Care
- Exchange
- BLFS Nasdaq
- COGT Nasdaq
- Market Cap
- BLFS 1.2B
- COGT 900.3M
- IPO Year
- BLFS 1989
- COGT 2018
- Fundamental
- Price
- BLFS $27.03
- COGT $7.87
- Analyst Decision
- BLFS Strong Buy
- COGT Buy
- Analyst Count
- BLFS 7
- COGT 6
- Target Price
- BLFS $29.00
- COGT $14.20
- AVG Volume (30 Days)
- BLFS 321.7K
- COGT 1.8M
- Earning Date
- BLFS 11-12-2024
- COGT 02-24-2025
- Dividend Yield
- BLFS N/A
- COGT N/A
- EPS Growth
- BLFS N/A
- COGT N/A
- EPS
- BLFS N/A
- COGT N/A
- Revenue
- BLFS $146,957,000.00
- COGT N/A
- Revenue This Year
- BLFS N/A
- COGT N/A
- Revenue Next Year
- BLFS N/A
- COGT N/A
- P/E Ratio
- BLFS N/A
- COGT N/A
- Revenue Growth
- BLFS 16.40
- COGT N/A
- 52 Week Low
- BLFS $14.50
- COGT $4.28
- 52 Week High
- BLFS $28.88
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- BLFS 55.27
- COGT 33.60
- Support Level
- BLFS $25.52
- COGT $7.42
- Resistance Level
- BLFS $28.63
- COGT $8.06
- Average True Range (ATR)
- BLFS 1.65
- COGT 0.66
- MACD
- BLFS -0.05
- COGT -0.03
- Stochastic Oscillator
- BLFS 63.05
- COGT 17.69
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.